| Literature DB >> 28389276 |
K S Baker1, J Campos2, M Pichel2, A Della Gaspera2, F Duarte-Martínez3, E Campos-Chacón3, H M Bolaños-Acuña3, C Guzmán-Verri4, A E Mather5, S Diaz Velasco6, M L Zamudio Rojas6, J L Forbester7, T R Connor8, K H Keddy9, A M Smith9, E A López de Delgado10, G Angiolillo10, N Cuaical10, J Fernández11, C Aguayo11, M Morales Aguilar12, C Valenzuela12, A J Morales Medrano12, A Sirok13, N Weiler Gustafson14, P L Diaz Guevara15, L A Montaño15, E Perez16, N R Thomson17.
Abstract
OBJECTIVES: Shigella sonnei is a globally important diarrhoeal pathogen tracked through the surveillance network PulseNet Latin America and Caribbean (PNLA&C), which participates in PulseNet International. PNLA&C laboratories use common molecular techniques to track pathogens causing foodborne illness. We aimed to demonstrate the possibility and advantages of transitioning to whole genome sequencing (WGS) for surveillance within existing networks across a continent where S. sonnei is endemic.Entities:
Keywords: Antimicrobial resistance; Central America; Diarrhoeal disease; Epidemiology; Genomics; Shigellosis; South America
Mesh:
Substances:
Year: 2017 PMID: 28389276 PMCID: PMC5667938 DOI: 10.1016/j.cmi.2017.03.021
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 8.067
Shigella sonnei isolates studied
| Study | Country | Years | |
|---|---|---|---|
| Latin America | Argentina | 2002–2011 | 50 |
| Chile | 2010–2011 | 27 | |
| Colombia | 2008–2011 | 31 | |
| Costa Rica | 2002–2010 | 50 | |
| Guatemala | 2011–2012 | 30 | |
| Paraguay | 2008–2012 | 18 | |
| Peru | 1999–2012 | 48 | |
| Uruguay | 2000–2011 | 28 | |
| Venezuela | 1997–2014 | 41 | |
| Global | Many | 1943–2008 | 116 |
Fig. 1Distribution of 323 Latin American Shigella sonnei isolates sequenced as part of this study by year and country (top), sublineage designation and year (middle), and sublineage and country (bottom).
Fig. 2Genomic portrait of Latin American (LA) Shigella sonnei in context. Maximum likelihood phylogenetic tree of S. sonnei showing 323 LA isolates. LA sublineages are shown in black and labelled with adjacent arcs; topology unlinked with LA isolates is shown in grey, with lineages labelled to the inner of the tree. Country of origin of LA isolates is shown on internal track at tips of tree, coloured according to map. Presence of predicted antimicrobial resistance is shown in outer tracks according to inlaid key. Global reference isolates in tree do not have country or resistance labels.
Genomic and epidemiologic features of Latin American Shigella sonnei
| Characteristic | Lineage | Sublineage | |||
|---|---|---|---|---|---|
| V | LAIIa | LAIIb | LAIIIa | LAIIIb | |
| Isolate features | |||||
| No. of isolates | 26 (8%) | 66 (20%) | 57 (18%) | 89 (28%) | 85 (26%) |
| Years | 1997–2009 | 1999–2012 | 1997–2014 | 1999–2012 | 2002–2012 |
| No. of countries | 4 | 5 | 6 | 6 | 5 |
| Pairwise distances (SNPs) | |||||
| Average | 134 | 176 | 161 | 95 | 105 |
| Median | 160 | 208 | 210 | 95 | 118 |
| Largest distance | 221 | 295 | 309 | 292 | 172 |
| Previous sublineage name | — | Unnamed | Unnamed | South America (III) | Africa/South America, within Global III |
LA, Latin America; SNP, single nucleotide polymorphism.
According to [14].
Fig. 3Phylogeography of Latin American (LA) Shigella sonnei. Midpoint rooted phylogenetic tree with taxa coloured by LA lineage or sublineage (reference isolates shown in grey). Distribution of each lineage or sublineage across LA is shown in maps, and for all sublineages and lineages in Costa Rica.
Fig. 4Argentine Shigella sonnei outbreaks in context of Latin American regional overview. Midpoint rooted phylogenetic tree shows phylogenetic positions of outbreak isolates from outbreaks in 2010, 2011 and 2016 using data generated locally in Argentina. Tree is labelled similarly to Fig. 2, with additional outbreak isolates being coloured by year (according to inlaid key) in outermost track exterior to country labels (coloured according to map).
Predicted resistance phenotypes and major resistance determinants
| Characteristic | Lineage | Sublineage | All ( | |||
|---|---|---|---|---|---|---|
| V ( | LAIIa ( | LAIIb ( | LAIIIa ( | LAIIIb ( | ||
| Predicted resistant | ||||||
| Aminoglycoside | 81% | 58% | 70% | 90% | 100% | 82% |
| β-Lactam | 42% | 59% | 35% | 90% | 7% | 48% |
| Phenicol | 0 | 2% | 0 | 89% | 0 | 25% |
| Trimethoprim | 85% | 61% | 68% | 81% | 100% | 80% |
| Sulphonamide | 46% | 62% | 30% | 83% | 87% | 67% |
| Tetracycline | 73% | 30% | 25% | 90% | 91% | 65% |
| Macrolide | 0 | 0 | 0 | 0 | 1% | 0 |
| Quinolone | 0 | 0 | 0 | 9% | 0 | 3% |
| ESBL | 4% | 0 | 0 | 0 | 0 | 0 |
| MDR | ||||||
| MDR | 81% | 62% | 51% | 91% | 91% | 77% |
| Average no. of AMR phenotypes per isolate | 3.3 | 2.7 | 2.3 | 5.3 | 3.9 | 3.7 |
| No. of unique resistance profiles | 9 | 11 | 13 | 11 | 6 | 30 |
| Previously described major AMR determinants | ||||||
| Aminoglycoside | — | Int2/Tn7 with | Int2/Tn7 | SRL | Int2/Tn7 and SpA | — |
| β-Lactam | — | Int2/Tn7 with | — | SRL | — | — |
| Phenicol | — | — | — | SRL | — | — |
| Trimethoprim | — | Int2/Tn7 | Int2/Tn7 | SRL | SpA | — |
| Sulphonamide | — | — | pABC-3 | Int2/Tn7 | — | |
| Tetracycline | — | — | pABC-3 | SpA | — | |
| Macrolide | — | — | — | — | — | |
| Quinolone | — | — | — | — | ||
AMR, antimicrobial resistance; ESBL, extended-spectrum β-lactamase; LA, Latin America; MDR, multidrug resistant; SNP, single nucleotide polymorphism.